Investigational drug shows promise for GERD patients

02/3/2010 | Medscape (free registration)

Long-acting arbaclofen placarbil reduced acid reflux episodes in gastroesophageal reflux disease patients over a 12-hour period, according to a report in the American Journal of Gastroenterology. The treatment is an investigational prodrug of the active R-isomer of baclofen, which has been used for GERD but is limited by a short half-life and poor tolerability.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ